RxDoctor Payments Data

Shaikh Nadeem

Psychiatric/Mental Health · Lincolnshire, ILNPI 1114695178

Payments from drug & device makers

$1,391in general payments, 2019–2025

Across 27 payments — averaging $51.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$636
  • AbbVie$283
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$157
  • Johnson & Johnson$155
  • Neurocrine Biosciences, Inc.$75
  • Braeburn Inc.$59
  • plus $27 from 1 others

What the payments were for

  • Food & beverage$1,27992%
  • Education$1118%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,391 in reported general payments places this provider in the 70th percentile of 922 psychiatric/mental health providers in Illinois.

See all psychiatric/mental health providers in Illinois

Medicare billing

Part B allowed, 2024
$7,105
Medicare patients
31
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate21$51,685
Aripiprazole23$4,354
Clozapine32$2,111
Olanzapine71$1,559
Fluphenazine Hcl13$1,304
Hydroxyzine Hcl44$1,237
Bupropion XlBupropion Hcl54$1,105
Carbamazepine25$1,030
Divalproex Sodium ErDivalproex Sodium11$890
Quetiapine Fumarate18$573
Divalproex Sodium11$545
Benztropine Mesylate42$497
Alprazolam21$288
Lithium Carbonate50$280
Prazosin Hcl16$275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$155$51,68521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 922 psychiatric/mental health providers in Illinois.

Other psychiatric/mental health in Lincolnshire

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →